glycovax, Author at Glycovax Pharma

Glycovax Pharma develops a vaccine against COVID-19 – A semi-synthetic vaccine in the preclinical phase

Glycovax Pharma develops a vaccine against COVID-19 – A semi-synthetic vaccine in the preclinical phase MONTREAL, Canada, April 21, 2020 – Glycovax Pharma, a biopharmaceutical company based in Montréal, is actively working on the development of a new vaccine approach to counter COVID-19. The prototype glycoconjugate vaccine is currently in the preclinical phase. Since the […]

Glycovax Pharma Files a Patent Application for a New Semi-Synthetic Vaccine against Breast Cancers

Press release / glycovax

Glycovax Pharma Files a Patent Application for a New Semi-Synthetic Vaccine against Breast Cancers MONTREAL, April 4, 2018 – Glycovax Pharma Inc. (“Glycovax” or “the Company”), a leader in the development of new therapeutic strategies against cancer and infectious diseases, announced today that it has filed a patent application with the United States Patent and Trademark Office, entitled “Precision

Glycovax Pharma Files a Patent Application for a New Semi-Synthetic Vaccine against Breast Cancers Read More »